Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia; Insulin Resistance
Intervention: Aripiprazole (Drug); Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s): David C. Henderson, MD, Principal Investigator, Affiliation: Massachusetts General Hospital
Summary
This study will evaluate the effects of combination treatment with aripiprazole and
clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with
schizophrenia.
Clinical Details
Official title: Aripiprazole for Clozapine Associated Medical Morbidity
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change in Total CholesterolChange in Weight Change in Body Mass Index (BMI) Change in Glucose Metabolism Change in Triglycerides Change in Insulin Resistance
Detailed description:
Schizophrenia is a severely disabling brain disorder. People with schizophrenia often
experience hallucinations and delusions, as well as overall difficulty with everyday
functioning. Although the medications available to treat the disorder are generally
effective, many cause undesirable side effects. Clozapine, for example, is a strong
tranquilizer that functions like an antipsychotic medication. It has been shown to be
effective in reducing the symptoms of schizophrenia, but can bring about serious side
effects, including heart failure, weight gain, and diabetes. Aripiprazole, an atypical
antipsychotic medication, has been shown to have fewer side effects than older antipsychotic
drugs. The addition of aripiprazole to a clozapine treatment regimen may reduce the negative
side effects of clozapine. This study will evaluate the effects of combination treatment
with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in
people with schizophrenia.
Individuals interested in participating in this 8-week, double-blind study will first attend
a screening session at the study site. Medical and psychiatric evaluations will be
completed, blood samples will be taken, and an EKG will be performed. Eligible participants
will undergo baseline assessments and then be randomly assigned to receive either
aripiprazole or placebo in addition to their prescribed dose of clozapine. Participants will
take one 15-mg capsule of their assigned medication once a day for 8 weeks. Study visits
will occur biweekly for the first 8 weeks, followed by one final follow-up visit at Week 12.
At each study visit, medication will be distributed, and the following criteria will be
assessed: vital signs; weight; complete blood count; medication side effects; and
extrapyramidal symptoms (EPS), which are potential neurological side effects of
antipsychotic medications and may include involuntary movements, tremors, and rigidity. The
Week 8 visit will include an EKG, and assessments of the following criteria: vital signs;
medication side effects; treatment efficacy; blood counts; weight and height; and waist and
hip circumference. At baseline and Week 8, participants will also undergo a frequently
sampled intravenous glucose tolerance test (FSIVGTT). This involves intravenous infusion of
glucose followed by frequent blood sampling to measure insulin and glucose concentrations.
During the 4 days prior to each FSIVGTT, participants will record their food intake and wear
an activity monitor.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of schizophrenia (any subtype) or schizoaffective disorder (any subtype)
- Treatment with clozapine for at least 1 year
- Stable dose of clozapine for at least 1 month
- Well established compliance with outpatient medications
- Female participants of non-childbearing potential or of childbearing potential and
willing to practice appropriate birth control methods (complete abstinence from
sexual intercourse, female sterilization, sterilization of male partner, implants of
levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or
double barrier methods of contraception using spermicide with either a condom or
diaphragm) during the study
Exclusion Criteria:
- Current substance abuse
- Psychiatrically unstable
- Significant medical illness, including severe cardiovascular, hepatic, or renal
disease
- History of immunosuppression
- Current or recent radiation or chemotherapy treatment for cancer
- Chronic use of steroids
- Pregnant or breastfeeding
Locations and Contacts
Massachusetts General Hospital Schizophrenia Program, Boston, Massachusetts 02114, United States
Additional Information
Related publications: Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG; Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003 Apr;166(4):391-9. Epub 2003 Feb 28. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999 Sep-Oct;40(5):438-43. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999 Jun;84(6):1932-7. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000 Jun;157(6):975-81. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 1;61(2-3):123-36. Visser M, Fuerst T, Lang T, Salamone L, Harris TB. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study--Dual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol (1985). 1999 Oct;87(4):1513-20. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002 Oct;63(10):856-65.
Starting date: March 2005
Last updated: June 10, 2014
|